Philip Tsai
Fortuna: 945 239 $ al 31/05/2026
Fortuna: 945 239 $ al 31/05/2026
Philip Tsai currently works at Immunome, Inc., as Chief Technical Officer from 2024.
Dr. Tsai also formerly worked at Seagen, Inc., as Senior Vice President-Technical Development from 2021 to 2024.
Dr. Tsai received his graduate degree and doctorate degree from California Institute of Technology and undergraduate degree from the University of Illinois At Urbana–Champaign.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
IMMUNOME, INC. 0,04 % | 19/12/2025 | 43.300 ( 0,04 % ) | 945 239 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| IMMUNOME, INC. | Director Técnico/Científico/I+D | 27/06/2024 |
| Empresas | Cargo | Fin |
|---|---|---|
| SEAGEN INC. | Director Técnico/Científico/I+D | 01/04/2024 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Seagen, Inc.
Seagen, Inc. Pharmaceuticals: MajorHealth Technology Develops monoclonal antibody-based therapeutic products for treatment of cancer and immunologic diseases | Health Technology |
Immunome, Inc.
Immunome, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which discovers, develops and commercializes antibody therapeutics | Health Technology |
California Institute of Technology
California Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois At Urbana–Champaign
University of Illinois At Urbana–Champaign Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.